Antares Pharma Appoints Tram Bui as Vice President of Corporate Communications and Investor Relations

Jack Howarth Retires as Vice President of Corporate Affairs

EWING, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced the appointment of Tram Bui as Vice President of Corporate Communications and Investor Relations.  Ms. Bui will succeed Jack Howarth, Vice President of Corporate Affairs, upon his retirement on August 31, 2020. Tram will report to Fred Powell, Antares Pharma’s Chief Financial Officer.

“I am excited to welcome Tram to Antares to lead our corporate communications and investor relations strategy. We look forward to leveraging her extensive industry experience and strong relationships with the investment community as the Company continues on its growth trajectory,” said Fred M. Powell, Executive Vice President and Chief Financial Officer of the Company. “I would also like to thank Jack for his dedication and many contributions to the company since 2012. He has been instrumental to the development of the Company’s communications strategy and we wish him the best of luck in his retirement.”  

Ms. Bui joins Antares Pharma with over 15 years of equity research, communications and investor relations experience. Most recently, she served as Senior Vice President, Investor Relations at The Ruth Group, a boutique investor relations and communications firm specializing in life science and medical technology industries.  Prior to The Ruth Group, Ms. Bui served as a Director at KCSA Strategic Communications, a public and investor relations agency, focused on developing successful investor communications platforms and capital raises for a broad base of public healthcare companies.  Previously, she was a buy-side healthcare analyst for a small cap fund at Lazard Asset Management and served as an institutional equity sales associate at CJS Securities. Ms. Bui received her Bachelor of Science in Marketing from the University of New Orleans.

About Antares Pharma

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia).  Antares Pharma’s FDA approved products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.